Treatment for Jaundice, Neonatal

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Chicago, Chicago, IL
Jaundice, Neonatal+1 More
Eligibility
< 18
All Sexes
What conditions do you have?
Select

Study Summary

A cross-sectional conductive study at the University of Chicago Medicine facilities (hospital and outreach clinics) to enable high qualitative estimation of bilirubin levels in the blood of newborns, independent of skin color, using Picterus JP.

Eligible Conditions

  • Jaundice, Neonatal

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 3-6months

3-6 months
Correlate estimates of bilirubin levels obtained by Picterus JP with TSB, TcB and VA in newborns with high melanin content in the skin.
Determine the accuracy of Picterus JP in newborns with high melanin content in the skin.
Enable high qualitative estimation of bilirubin levels in the blood of newborns, independent of skin color, using Picterus JP.
3-6months
Adapt the current algorithm of Picterus JP to newborns with high melanin content in the skin.

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

250 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3-6months
Closest Location: University of Chicago · Chicago, IL
Photo of University of Chicago  1Photo of University of Chicago  2Photo of University of Chicago  3
2004First Recorded Clinical Trial
1 TrialsResearching Jaundice, Neonatal
705 CompletedClinical Trials

Eligibility Criteria

Age < 18 · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Infants aged 1 month or less are not eligible for this test.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.